Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.
The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated "significant improvement" in overall response rate.
The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.
Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.
Price: 2.08, Change: +0.21, Percent Change: +11.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.